Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions

In 2024, blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions trade exhibited strong growth, with global flows reaching $46,749,528,764 and a three-year compound annual growth rate of +12.7% (five-year: +9.5%). The all-time peak of $46,749,528,764 was recorded in 2024.

Over the 13-year observation window (2012–2024), 100% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is steady (+2.7% acceleration).

The supply side is diversified (Herfindahl-Hirschman Index 0.136). The three largest exporters — United States ($11.8B), Germany ($9.5B), and Switzerland ($5.3B) — collectively dominate supply flows. The leading exporter has grown at +15.6% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.090). The three largest import markets are United States ($8.5B), Germany ($7.5B), and Switzerland ($5.5B). The largest importing market sources from 91 different supplying countries.

The dominant trade corridor is United States → Germany at $2.9B, representing 37.9% of the importer's total demand.

The volatility score for blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions is 9 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.